A recent phase I trial investigating the use of NK-cell therapy in combination with trastuzumab in HER2-positive cancer patients demonstrated that the therapy was well tolerated and that target engagement and anti-tumour activity was seen in the patients (115). Here, ERBB2 is linked to cancer.